Announcements

Index reconstitution notices and updates

  • March 2026

    Q1 2026 Index Review Complete

    The quarterly review of LSCIBP and LSCIBC eligibility criteria has been completed. No interim changes to either index.

  • December 2025

    Semi-Annual Reconstitution — December 2025

    LSCIBP and LSCIBC have been reconstituted effective market open December 22, 2025. Updated constituent lists reflect current FDA approval status and clinical trial classifications.

  • June 2025

    Semi-Annual Reconstitution — June 2025

    LSCIBP and LSCIBC have been reconstituted effective market open June 23, 2025. Component counts: LSCIBP 63, LSCIBC 126.

  • December 2024

    Semi-Annual Reconstitution — December 2024

    Both indexes reconstituted effective December 23, 2024. LSCIBP: 61 components. LSCIBC: 119 components.

  • June 2024

    Semi-Annual Reconstitution — June 2024

    Semi-annual reconstitution completed. LSCIBP: 59 components. LSCIBC: 115 components.

  • December 2023

    Semi-Annual Reconstitution — December 2023

    Both indexes reconstituted effective December 18, 2023.